Home >
Medicine Info >
Abamune-L Baby Tablet
Loading interface...

Abamune-L Baby Tablet

Manufactured byCIPLA LTD
ContainsAbacavir (60 mg) + Lamivudine (30 mg)
Description
Abamune-L Baby Tablet is a combination medicine used to treat human immunodeficiency virus (HIV) infections in children. This medicine is not a cure for HIV; it only prevents the virus from multiplying in your body. Monitoring of liver function and kidney function may be necessary while receiving this medicine based on the clinical condition of the patient.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Abamune-L Baby Tablet

  • Chills and fever
  • Diarrhea
  • Headache
  • Fatigue
  • Loss of appetite
  • Depression
  • Stuffy nose
  • Muscle pain
  • Heartburn
  • Indigestion
  • Sore throat
  • Abdominal pain
  • Skin Rash
  • Unusual tiredness
  • Trouble sleeping
  • Buffalo hump

Uses of Abamune-L Baby Tablet

What is it prescribed for?

  • HIV infection
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The time required for this medicine to show its effect is not clinically established.
  • How long do the effects of this medicine last?
    The time until which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women.

Allergy

This medicine is not recommended for use in patients with a known allergy to abacavir, lamivudine, or any other inactive ingredients present along with these medicines.

Renal impairment

This medicine is not recommended for use in patients with a creatinine clearance of less than 50 ml/min.

HLA-B*5701-positive patients

This medicine is not recommended for use in patients who have screened positive for human leukocyte antigen HLA-B*5701 due to the increased risk of severe hypersensitivity reactions.

Liver impairment

This medicine is not recommended for use in patients with liver impairment due to the increased risk of serious adverse effects.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women.

Breast-feeding

This medicine is not recommended for use in breastfeeding women.
General warnings

Immune reconstitution syndrome

This medicine should be used with caution due to the increased risk of Immune reconstitution syndrome. Report any unusual symptoms to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Lactic acidosis

This medicine should be used with caution due to the increased risk of Lactic acidosis. Report any unusual symptoms to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Fat Redistribution

This medicine may cause fat gain or fat loss from the body. This may result in peripheral wasting, facial wasting, Cushingoid appearance, etc. Close monitoring of body weight and body fat distribution is necessary while receiving this medicine. Any changes in the body should be informed to the doctor on priority.

Diabetes

This medicine may alter the blood glucose levels and may also increase the risk of new-onset diabetes mellitus. Close monitoring of blood glucose levels is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Pancreatitis

This medicine may cause pancreatitis in some patients. Report any unusual symptoms to the doctor immediately. Therapy may need to be discontinued if the patient develops any signs or symptoms of pancreatitis.

Alcohol containing medicines

This medicine should be used with extreme caution in patients taking/receiving medications containing alcohol due to the increased risk of severe adverse effects.

Missed Dose

Take/administer the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Epirubicin

Methotrexate

Ribavirin

Efavirenz

Disease interactions

Renal Dysfunction

This medicine should be used with extreme caution in patients with renal diseases due to the increased risk of severe adverse effects. Renal function should be assessed before initiating the treatment. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Cardiovascular disease

This medicine should be used with caution in patients with a history of heart diseases and active heart disease due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is advised during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take this medicine exactly as instructed by the doctor. Do not take/administer in larger or smaller quantities than recommended. Ensure that proper hygiene measures are adopted. Complete the course of treatment to prevent the spread of the infection. Close monitoring of liver function and kidney function may be necessary while receiving this medicine based on the clinical condition.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine works by stopping the human immunodeficiency virus (HIV) from multiplying. This helps in reducing the chances of development of acquired immunodeficiency syndrome (AIDS) and other HIV-related illnesses.
Legal Status

Approved

Approved

Unknown

Unknown

Classification

Category

Antiviral combinations, Nucleoside reverse transcriptase inhibitors (NRTIs)

Schedule

Schedule H

[Internet]. Extranet.who.int. 2018 [cited 4 September 2018]. Available from:

https://extranet.who.int/prequal/sites/default/files/documents/HA518part6.pdf

[Internet]. Accessdata.fda.gov. 2018 [cited 4 September 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202381s000ltr.pdf

[Internet]. Dndi.org. 2018 [cited 4 September 2018]. Available from:

https://www.dndi.org/images/stories/diseases_portfolio/DNDi_Paediatric_HIV_roundtable.pdf

Mylan's tentative FDA approval for paeds formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI | ViiV Healthcare [Internet]. Viivhealthcare.com. 2018 [cited 4 September 2018]. Available from:

https://www.viivhealthcare.com/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai.aspx

Abacavir: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 19 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a699012.html

Lamivudine - DrugBank [Internet]. Drugbank.ca. 2017 [cited 29 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB00709
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 16 Oct 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.